RecruitingNCT06064682

An Organoid-based Functional Precision Medicine Trial in Osteosarcoma

An Organoid-based Functional Precision Medicine Trial in Osteosarcoma: PREMOST


Sponsor

Jonsson Comprehensive Cancer Center

Enrollment

40 participants

Start Date

Feb 12, 2024

Study Type

OBSERVATIONAL

Conditions

Summary

The purpose of this study is to examine if we can predict sensitivity of osteosarcoma to different chemotherapy agents using tissue cultures in the laboratory. We know that different chemotherapy agents can be used in the treatment, but not every sarcoma responds to them equally. It is important to understand if testing of the tissue obtained during a routine biopsy or surgery may be useful in selecting appropriate treatments. In addition, additional testing of the tumor, including genetic testing, will help us to understand osteosarcoma better.


Eligibility

Plain Language Summary

Simplified for easier understanding

This study uses lab-grown "mini-tumors" (organoids) made from a patient's own bone cancer tissue to figure out which treatments are most likely to work for that specific person — a personalized approach to treating osteosarcoma (a type of bone cancer). **You may be eligible if...** - You have imaging that suggests osteosarcoma (bone cancer) and are scheduled for a biopsy or surgery - You may or may not already have a confirmed diagnosis — the study includes both groups - The cancer may or may not have spread (metastatic cases are also eligible) **You may NOT be eligible if...** - You are not scheduled for a biopsy or surgery - Your imaging does not suggest osteosarcoma Talk to your doctor to see if this trial is right for you.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

OTHERstandard of care biopsy

Image-guided or surgical biopsy of the lesion that is suspected to be osteosarcoma in a patient with localized disease (Group 1)

OTHERstandard of care biopsy

Image-guided or surgical biopsy or excision of the lesion that is suspected to be recurrent or metastatic osteosarcoma (Group 2).


Locations(1)

UCLA / Jonsson Comprehensive Cancer Center

Los Angeles, California, United States

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT06064682


Related Trials